Molecular diagnostics company Epigenomics has entered into a €5m convertible bond financing agreement with YA Global Master SPV Ltd. Pursuant to the terms of the agreement, YA Global Master SPV will purchase convertible notes with a ...
Tags: Epigenomics, Molecular diagnostics
US-based genomics company BioNano Genomics has launched Irys System for genome mapping in the region of European Union (EU). The Irys benchtop instrument is fully automated and uses the IrysChip to uncoil and confine long DNA molecules in ...
Tags: Bionano, Irys System
Clinical diagnostics company BioChain has licensed Epigenomics' methylated Septin9 marker, designed for the blood based detection of colorectal cancer (CRC). Under the license, BioChain will offer Septin9 assay as a service to customers ...
Tags: Clinical diagnostics, BioChain, Epigenomics
Bruker was a key sponsor of the inaugural OMICS Australasia 2012 Symposium, hosted by Murdoch University and supported by the Western Australian Department of Commerce and other industry sponsors. The symposium was held in Fremantle, Perth, ...
Tags: Bruker, sponsor, OMICS Australasia, 2012 Symposium
Epigenomics has released additional results from the comparative study aimed to know non-inferiority of Epi proColon assay performance in comparison to fecal immunochemical testing (FIT). The additional data had shown that Epi proColon ...
Tags: Epigenomics, additional data, Epi proColon, Medicine
Epigenomics has reported positive results from a clinical study, which showed that its blood-based colorectal cancer (CRC) detection test is non-inferior in sensitivity when compared to fecal immunochemical testing (FIT). Using patients ...
Tags: Epigenomics, blood-based colorectal cancer, non-inferior in sensitivity
Epigenomics has announced results from a comparative study between its blood-based colorectal cancer(CRC)detection test Epi proColon and fecal immunochemical testing(FIT)to demonstrate the non-inferiority of Epi proColon in detection of ...
Tags: Epigenomics, CRC, FIT, Epi proColon